Publication | Open Access

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial

Advanced EsophagealSurgical OncologyEsophagusEsophageal CancerGastroesophageal JunctionGastrointestinal OncologyMedicineGastroenterologySurgeryGastric AdenocarcinomaOncologyRadiation Oncology